Endocrine Abstracts

Background: Patients with adrenal insufficiency (AI) exhibit increased morbidity, mortality and impaired quality of life (QoL) and conventional hydrocortisone replacement does not mimic the endogenous circadian pattern and may compromise adherence. A modified – release hydrocortisone formulation (Plenadren) for once-daily use is licensed in order to meet these needs.Objective: To audit the effects of treatment change from HC to Plenadren in an out-p...

Context: The nadir serum GH level during glucose suppression (OGTT) is recommended in patients treated by surgery, but not during SA treatment. We have shown that patients considered controlled by SA don’t suppress serum GH during OGTT and have impaired disease-specific QoL as compared to patients controlled by surgery. We hypothesize SA treated patients also don’t suppress GH in response to mixed meals.Aim: To compare GH levels during two mixe...

Background: Current guidelines recommend that susceptible patients should be tested and treated for AGHD. Still, it is not universally recognised as a distinct entity and reimbursement of GH replacement therapy is not available in some countries.Aim: 1) to record current practice of AGHD management throughout Europe and benchmark it against existing guidelines, 2) to evaluate educational status of health care professionals.Patients...

Background: Cross-sectional studies in small and selected populations indicate a relatively high prevalence of incipient and/or subclinical Cushing’s syndrome (CS) in patients with type 2 diabetes (T2D), which could have therapeutic implications.Aim: To estimate the prevalence of CS in a large, unselected cohort of recently diagnosed T2D patients.Methods: A total of 384 consecutive out – patients with T2D diagnosed after ...

Background: Hypercortisolism is prevalent in type 2 diabetes (T2D), but analytical and functional uncertainties prevail. Measurement of salivary cortisol is considered an expedient screening method for hypercortisolism, but its usefulness in the context of T2D is uncertain.Aim: To compare late night salivary cortisol (LNSC) with the 1 mg overnight dexamethasone suppression test (DST), which was considered ‘reference standard’, in T2D.<p cla...

Background: Serum IGFI measurements are used during GH replacement in GHDA for titration of the GH dose, to monitor compliance and to avoid overdosing, but it is uncertain if pretreatment IGFI is a determinant of the GH dose or the response to GH treatment.Methods: Data from the NordiNet IOS have been analyzed to determine pretreatment serum IGFI concentrations in GHDA and to analyze if they influence the GH starting dose and/or the therapeutic response ...

Background: Data from several clinical studies have demonstrated the benefit of GH treatment in relation to bone mineral density and body composition in young adults who received GH treatment in childhood due to GHD1–3. There are recommendations to use a higher GH dose in the transition phase compared to the GH dose required during adulthood to mimic the endogenous GH secretion4,5.Methods: Data from NordiNet IOS have been analy...

Background: Somatostatin analogue treatment (SA) is used in acromegaly to suppress GH secretion and tumour growth. In addition, SA also suppresses insulin secretion and may impact on GH signalling in peripheral tissues.Objective: To compare GH and insulin signalling in skeletal muscle and adipose tissue in vivo before and after a single exogenous GH bolus in patients with acromegaly controlled by either surgery alone or by ongoing treatment with a slow-r...